Helen Frankenthaler Foundation

NS3/4A inhibitor research compound

Discovery of the HCV NS3/4A Protease Inhibitor (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key Steps in Structure-Based Optimization

pentapeptide 25 cas no 1000313 64 3 lab product clean

Abstract

The structures of both the native holo-HCV NS3/4A protease domain and the protease domain with a serine 139 to alanine (S139A) mutation were solved to high resolution. Subsequently, structures were determined for a series of ketoamide inhibitors in complex with the protease. The changes in the inhibitor potency were correlated with changes in the buried surface area upon binding the inhibitor to the active site. The largest contribution to the binding energy arises from the hydrophobic interactions of the P1 and P2 groups as they bind to the S1 and S2 pockets [the numbering of the subsites is as defined in Berger, A.; Schechter, I. Philos. Trans. R. Soc. London, Ser. B 1970, 257, 249−264]. This correlation of the changes in potency with increased buried surface area contributed directly to the design of a potent tripeptide inhibitor of the HCV NS3/4A protease that is currently in clinical trials.

ACS Publications

Copyright © 2007 American Chemical Society

Cited By

This article is cited by 97 publications.

  • Stephen Hanessian, Nicholas A. Meanwell. Structural Aspects of Proline Methanologues in Drug Design, Optimization, and Development. The Journal of Organic Chemistry 2026, 91 (9) , 3399-3446.
  • Vladimir Kubyshkin, Pavel K. Mykhailiuk. Proline Analogues in Drug Design: Current Trends and Future Prospects. Journal of Medicinal Chemistry 2024, 67 (22) , 20022-20055.
  • Simona Di Martino, Giovanna Li Petri, Maria De Rosa. Hepatitis C: The Story of a Long Journey through First, Second, and Third Generation NS3/4A Peptidomimetic Inhibitors. What Did We Learn?. Journal of Medicinal Chemistry 2024, 67 (2) , 885-921.
  • Melina Mottin, Bruna Katiele de Paula Sousa, Nathalya Cristina de Moraes Roso Mesquita, Ketllyn Irene Zagato de Oliveira, Gabriela Dias Noske, Geraldo Rodrigues Sartori, Aline de Oliveira Albuquerque, Fabio Urbina, Ana C. Puhl, José Teófilo Moreira-Filho, Guilherme E. Souza, Rafael V. C. Guido, Eugene Muratov, Bruno Junior Neves, João Hermínio Martins da Silva, Alex E. Clark, Jair L. Siqueira-Neto, Alexander L. Perryman, Glaucius Oliva, Sean Ekins, Carolina Horta Andrade. Discovery of New Zika Protease and Polymerase Inhibitors through the Open Science Collaboration Project OpenZika. Journal of Chemical Information and Modeling 2022, 62 (24) , 6825-6843.
  • Nicholas A. Meanwell, Gunda I. Georg, Shaomeng Wang. The 2020 Nobel Prize in Physiology or Medicine. Journal of Medicinal Chemistry 2020, 63 (22) , 13197-13204.
  • Maxwell D. Cummings, Sivakumar Sekharan. Structure-Based Macrocycle Design in Small-Molecule Drug Discovery and Simple Metrics To Identify Opportunities for Macrocyclization of Small-Molecule Ligands. Journal of Medicinal Chemistry 2019, 62 (15) , 6843-6853.
  • Djadé I. Soumana, Nese Kurt Yilmaz, Akbar Ali, Kristina L. Prachanronarong, and Celia A. Schiffer . Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease. Journal of the American Chemical Society 2016, 138 (36) , 11850-11859.
  • Dora Toledo Warshaviak, Gali Golan, Kenneth W. Borrelli, Kai Zhu, and Ori Kalid . Structure-Based Virtual Screening Approach for Discovery of Covalently Bound Ligands. Journal of Chemical Information and Modeling 2014, 54 (7) , 1941-1950.
  • Arthitaya Meeprasert, Supot Hannongbua, and Thanyada Rungrotmongkol . Key Binding and Susceptibility of NS3/4A Serine Protease Inhibitors against Hepatitis C Virus. Journal of Chemical Information and Modeling 2014, 54 (4) , 1208-1217.
  • Åsa Rosenquist, Bertil Samuelsson, Per-Ola Johansson, Maxwell D. Cummings, Oliver Lenz, Pierre Raboisson, Kenny Simmen, Sandrine Vendeville, Herman de Kock, Magnus Nilsson, Andras Horvath, Ronald Kalmeijer, Guy de la Rosa, and Maria Beumont-Mauviel . Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor. Journal of Medicinal Chemistry 2014, 57 (5) , 1673-1693.
  • Jörg Schröder, Anette Klinger, Frank Oellien, Richard J. Marhöfer, Michael Duszenko, and Paul M. Selzer . Docking-Based Virtual Screening of Covalently Binding Ligands: An Orthogonal Lead Discovery Approach. Journal of Medicinal Chemistry 2013, 56 (4) , 1478-1490.
  • Alexander Dömling, Wei Wang, and Kan Wang . Chemistry and Biology Of Multicomponent Reactions. Chemical Reviews 2012, 112 (6) , 3083-3135.
  • Wei Wang, Sarah Ollio, Eberhardt Herdtweck, and Alexander Dömling . Polycyclic Compounds by Ugi−Pictet−Spengler Sequence. The Journal of Organic Chemistry 2011, 76 (2) , 637-644.
  • Montse Llinàs-Brunet, Murray D. Bailey, Nathalie Goudreau, Punit K. Bhardwaj, Josée Bordeleau, Michael Bös, Yves Bousquet, Michael G. Cordingley, Jiamin Duan, Pat Forgione, Michel Garneau, Elise Ghiro, Vida Gorys, Sylvie Goulet, Ted Halmos, Stephen H. Kawai, Julie Naud, Marc-André Poupart and Peter W. White. Discovery of a Potent and Selective Noncovalent Linear Inhibitor of the Hepatitis C Virus NS3 Protease (BI 201335). Journal of Medicinal Chemistry 2010, 53 (17) , 6466-6476.
  • John A. McCauley, Charles J. McIntyre, Michael T. Rudd, Kevin T. Nguyen, Joseph J. Romano, John W. Butcher, Kevin F. Gilbert, Kimberly J. Bush, M. Katharine Holloway, John Swestock, Bang-Lin Wan, Steven S. Carroll, Jillian M. DiMuzio, Donald J. Graham, Steven W. Ludmerer, Shi-Shan Mao, Mark W. Stahlhut, Christine M. Fandozzi, Nicole Trainor, David B. Olsen, Joseph P. Vacca and Nigel J. Liverton . Discovery of Vaniprevir (MK-7009), a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor. Journal of Medicinal Chemistry 2010, 53 (6) , 2443-2463.
  • M. Emilia Di Francesco, Gabriella Dessole, Emanuela Nizi, Paola Pace, Uwe Koch, Fabrizio Fiore, Silvia Pesci, Jillian Di Muzio, Edith Monteagudo, Michael Rowley and Vincenzo Summa . Novel Macrocyclic Inhibitors of Hepatitis C NS3/4A Protease Featuring a 2-Amino-1,3-thiazole as a P4 Carbamate Replacement. Journal of Medicinal Chemistry 2009, 52 (22) , 7014-7028.
  • Bibek Pramanik, Animesh Naskar, Totan Ghosh, Sashi Debnath, Krishnendu Maji. Peptidomimetics as Emerging Inhibitor Against Mpro of SARS-CoV-2. Mini-Reviews in Organic Chemistry 2025, 22 (8) , 757-766.
  • Muya Xiong, Tianqing Nie, Haixia Su, Yechun Xu. Structure-based rational design of viral protease inhibitors: case studies of approved drugs. SCIENTIA SINICA Chimica 2025, 55 (8) , 2392-2420.
  • Sahani Sandalima Uthumange, Angie Jun Hui Liew, Xavier Wezen Chee, Keng Yoon Yeong. Ringing medicinal chemistry: The importance of 3-membered rings in drug discovery. Bioorganic & Medicinal Chemistry 2024, 116, 117980.
  • Ahmed M. Shawky, Faisal A. Almalki, Hayat Ali Alzahrani, Ashraf N. Abdalla, Bahaa G.M. Youssif, Nashwa A. Ibrahim, Mohammed Gamal, Hany A.M. El-Sherief, Maha M. Abdel-Fattah, Ahmed A. Hefny, Ahmed H. Abdelazeem, Ahmed M. Gouda. Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions. European Journal of Medicinal Chemistry 2024, 277, 116704.
  • Kanzal Iman, Muhammad Usman Mirza, Fazila Sadia, Matheus Froeyen, John F. Trant, Safee Ullah Chaudhary. Pharmacophore-Assisted Covalent Docking Identifies a Potential Covalent Inhibitor for Drug-Resistant Genotype 3 Variants of Hepatitis C Viral NS3/4A Serine Protease. Viruses 2024, 16 (8) , 1250.
  • Ritesh P. Bhole, Govinda O. Joshi, Harshad S. Kapare, Rupesh V. Chikhale, Somdatta Chaudhari. Covalent drug – An emerging framework for targeted drug development. Results in Chemistry 2024, 8, 101615.
  • Kihang Choi. The Structure-property Relationships of Clinically Approved Protease Inhibitors. Current Medicinal Chemistry 2024, 31 (12) , 1441-1463.
  • Yves L. Janin. On the origins of SARS-CoV-2 main protease inhibitors. RSC Medicinal Chemistry 2024, 15 (1) , 81-118.
  • Arun K. Ghosh, Monika Yadav. Synthesis of optically active SARS-CoV-2 Mpro inhibitor drug nirmatrelvir (Paxlovid): an approved treatment of COVID-19. Organic & Biomolecular Chemistry 2023, 21 (28) , 5768-5774.
  • Taťána Majerová, Jan Konvalinka. Viral proteases as therapeutic targets. Molecular Aspects of Medicine 2022, 88, 101159.
  • Arun K. Ghosh, Jennifer L. Mishevich, Andrew Mesecar, Hiroaki Mitsuya. Recent Drug Development and Medicinal Chemistry Approaches for the Treatment of SARS‐CoV‐2 Infection and COVID‐19. ChemMedChem 2022, 17 (22).
  • Matthias Göhl, Linlin Zhang, Haifa El Kilani, Xinyuanyuan Sun, Kaixuan Zhang, Mark Brönstrup, Rolf Hilgenfeld. From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease. Molecules 2022, 27 (13) , 4292.
  • H. Tarannum, K.M. Rashmi, S. Nandi. Exploring the SARS-Cov-2 Main Protease (Mpro) and RdRp Targets by Updating Current Structure-based Drug Design Utilizing Co-crystals to Combat COVID-19. Current Drug Targets 2022, 23 (8) , 802-817.
  • Naoya Shindo, Akio Ojida. Recent progress in covalent warheads for in vivo targeting of endogenous proteins. Bioorganic & Medicinal Chemistry 2021, 47, 116386.
  • Robert A. Nicholls, Marcin Wojdyr, Robbie P. Joosten, Lucrezia Catapano, Fei Long, Marcus Fischer, Paul Emsley, Garib N. Murshudov. The missing link: covalent linkages in structural models. Acta Crystallographica Section D Structural Biology 2021, 77 (6) , 727-745.
  • Khushboo Bafna, Kris White, Balasubramanian Harish, Romel Rosales, Theresa A. Ramelot, Thomas B. Acton, Elena Moreno, Thomas Kehrer, Lisa Miorin, Catherine A. Royer, Adolfo García-Sastre, Robert M. Krug, Gaetano T. Montelione. Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture. Cell Reports 2021, 35 (7) , 109133.
  • Mariusz Jaskolski, Zbigniew Dauter, Ivan G. Shabalin, Miroslaw Gilski, Dariusz Brzezinski, Marcin Kowiel, Bernhard Rupp, Alexander Wlodawer. Crystallographic models of SARS-CoV-2 3CL pro : in-depth assessment of structure quality and validation. IUCrJ 2021, 8 (2) , 238-256.
  • Daniel W. Kneller, Stephanie Galanie, Gwyndalyn Phillips, Hugh M. O'Neill, Leighton Coates, Andrey Kovalevsky. Malleability of the SARS-CoV-2 3CL Mpro Active-Site Cavity Facilitates Binding of Clinical Antivirals. Structure 2020, 28 (12) , 1313-1320.e3.
  • Lifeng Fu, Fei Ye, Feng Yu, Qisheng Wang, Yan Wu, Cheng Zhao, Huan Sun, Baoying Huang, Peihua Niu, Hao Song, Yi Shi, Xuebing Li, Wenjie Tan, Jianxun Qi, George Fu Gao. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nature Communications 2020, 11 (1).
  • Georg Dultz, Tetsuro Shimakami, Markus Schneider, Kazuhisa Murai, Daisuke Yamane, Antoine Marion, Tobias M. Zeitler, Claudia Stross, Christian Grimm, Rebecca M. Richter, Katrin Bäumer, MinKyung Yi, Ricardo M. Biondi, Stefan Zeuzem, Robert Tampé, Iris Antes, Christian M. Lange, Christoph Welsch. Extended interaction networks with HCV protease NS3-4A substrates e